Clobazam add-on therapy for drug-resistant epilepsy
Bresnahan, Rebecca Williamson, John Martin-McGill, Kirsty J. Michael, Benedict D. Marson, Anthony G.
Bresnahan, Rebecca
Williamson, John
Martin-McGill, Kirsty J.
Michael, Benedict D.
Marson, Anthony G.
Advisors
Editors
Other Contributors
Affiliation
EPub Date
Publication Date
2019-10-22
Submitted Date
Collections
Other Titles
Abstract
Epilepsy affects approximately 1% of the population, with up to 30% of patients continuing to have seizures, despite antiepileptic drug treatment. Clobazam is a 1,5‐benzodiazepine and is commonly used as an add‐on treatment for drug‐resistant epilepsy. This review is an updated version of the original Cochrane Review, first published in 2008, and examines the most current literature regarding clobazam as an add‐on for drug‐resistant epilepsy.
Citation
Bresnahan, R., Martin‐McGill, K. J., Williamson, J., Michael, B. D., & Marson, A. G. (2019). Clobazam add‐on therapy for drug‐resistant epilepsy. Cochrane Database of Systematic Reviews, (10). https://doi.org/10.1002/14651858.CD004154.pub5
Publisher
Wiley
Journal
Research Unit
DOI
10.1002/14651858.CD004154.pub5
PubMed ID
PubMed Central ID
Type
Article
Language
Description
This article is not available on ChesterRep